Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports.

ALK tyrosine kinase inhibitors (ALK TKIs) have improved prognosis in We present two patients with While preclinical models have showed encouraging data, there is a critical need for clinical studies on treatment strategies to overcome this drug resistance. Three real-life therapeutic approaches were used in this report: i) using brigatinib, an inhibitor targeting both ALK and EGFR tyrosine kinases; ii) combining two ALK TKIs together; and iii) delivering doublet platinum chemotherapy. In case 1, time to treatment failure (TTF) was 9.5 months with brigatinib; in case 2, TTF was 10 months with combined TKIs (osimertinib and brigatinib), whereas TTF with chemotherapy was only 2 months. Tolerability profile TKIs combotherapy was acceptable. These case reports underline the therapeutic complexity of

Informations de copyright

Copyright © 2023 Michaux, Perrier, Mehlman, Alshehhi, Dubois, Lacave, Coulet, Cadranel and Fallet.

Déclaration de conflit d'intérêts

LM received support for attending meetings and travels from Bristol Myers Squibb and Olympus, all outside of the submitted work. CM received support for attending meeting and travel from ISIS Medical; outside of the submitted work. AD received support for attending meetings and travels from Astellas, Janssen, Bristol Myers Squibb, and Amgen, all outside of the submitted work. FC received payment for her institution for educational events from Astra Zeneca, outside of the submitted work. JC received grants for his institution from Pfizer, AbbVie, Sanofi, and Sophia Genetics; payment for participation to boards of experts from Amgen, Aztra Zeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Merck Sharp and Dohme, Novartis, Pfizer, and Takeda; all outside of the submitted work. VF received payment for lectures from Pfizer, Takeda, Bristol Myers Squibb, Aztra Zeneca, Roche, and Boehringer Ingelheim; support for attending meetings and travels from Takeda, Janssen, Pfizer, Aztra Zeneca, and Novartis; all outside of the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.